AC Immune (NASDAQ:ACIU) Trading Up 11.2%
AC Immune SA (NASDAQ:ACIU) was up 11.2% during trading on Wednesday . The company traded as high as $5.98 and last traded at $5.84. Approximately 500,103 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 439,165 shares. The stock had previously closed at $5.25.
A number of equities research analysts recently commented on ACIU shares. BidaskClub downgraded AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research downgraded AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Finally, ValuEngine upgraded AC Immune from a “sell” rating to a “hold” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. AC Immune currently has a consensus rating of “Hold” and an average price target of $11.94.
The company has a debt-to-equity ratio of 0.01, a current ratio of 5.06 and a quick ratio of 5.06. The stock has a market capitalization of $365.85 million, a P/E ratio of -7.12 and a beta of -0.16.
A number of hedge funds have recently modified their holdings of the business. BVF Inc. IL raised its position in AC Immune by 234.3% during the first quarter. BVF Inc. IL now owns 7,455,534 shares of the company’s stock valued at $37,650,000 after purchasing an additional 5,225,507 shares during the period. FMR LLC raised its position in AC Immune by 7.7% during the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock valued at $53,039,000 after purchasing an additional 403,086 shares during the period. Prosight Management LP purchased a new stake in AC Immune during the first quarter valued at approximately $3,588,000. BlackRock Inc. raised its position in AC Immune by 8.3% during the first quarter. BlackRock Inc. now owns 698,002 shares of the company’s stock valued at $3,525,000 after purchasing an additional 53,327 shares during the period. Finally, Renaissance Technologies LLC raised its position in AC Immune by 215.1% during the first quarter. Renaissance Technologies LLC now owns 220,250 shares of the company’s stock valued at $1,112,000 after purchasing an additional 150,350 shares during the period. Institutional investors and hedge funds own 26.54% of the company’s stock.
AC Immune Company Profile (NASDAQ:ACIU)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Read More: Dividend Aristocrat Index
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.